Key Takeaways
- Soft quarter, specific reasons: Revenue fell 4% YoY because a high-margin order worth nearly ₹1 crore was postponed to H2 FY27, dragging CDMO EBITDA margin to 6.3% from 17.9%. Management calls the outlook promising.
- India entity set to surge: Revenue is guided to rise at least 30–35% in FY27, with operating margin near 10%, driven by tech transfers from Switzerland and new commercial projects.
- Balance sheet repair is underway: A promoter fundraise of up to CHF 20 crore is expected in 60–90 days, with proceeds earmarked to prepay high-cost India debt and fund future needs.
- FY28–29 ambition is explicit: Management targets >10% revenue growth and an EBITDA margin closer to 25–26%, the level achieved before the EDQM issues, as French entities scale and India operations expand.
- What to watch next quarter: Whether the postponed Q1 order ships and converts to EBITDA, progress on the three tech transfers in advanced discussion, and closure of the promoter fundraise.
Q1 Performance: The Deferred Order
- The missing order: One order expected to ship in Q1 was postponed to the latter half of the financial year, representing almost ₹1 crore of value and a significant amount of operating profit. Had it accrued, the quarter would have looked very different.
- CDMO margin collapse: CDMO EBITDA margin fell to 6.3% from 17.9% YoY, driven by the deferred revenue and an ₹11.73 crore foreign exchange loss, mainly from USD/CHF fluctuation.
- Marketable Molecules held up: Segment revenue grew significantly YoY (₹143.2 crore vs ₹96.8 crore) on higher cholesterol sales, though margin normalized lower because Q1 FY26 had a large amount of high-margin analogue sales.
- Specialty (VDA) improved: Vitamin D and analogues business increased both sales and margin, helped by access to new wool grease sources with more attractive prices.
- Cost control underway: Cost reduction programs across the specialty business unit are ongoing and showing first signs; drug product cost control is being rigorously pursued.
- Revenue lumpiness is structural: QoQ swings are inherent in the B2B, new-chemical-entity model; shipments are driven by customer demand, molecule performance, and market needs, with Q4 historically the strongest quarter. Post-pandemic customer destocking is still occurring.
- Fixed cost leverage: Employee cost (~50% of P&L) and other expenses (~16%) are largely fixed; only COGS are completely variable. Incremental revenue translates at roughly 70% to EBITDA, making top-line growth the primary margin driver.
Harshil Dalal: "If you're talking about CHF1 crore of revenue, this could translate close to70% addition to the EBITDA. That's how the mechanics work. The more we are able to work on the top line, the more it will translate straight away into the EBITDA."
India Entity Ramp-Up & Tech Transfers
- India revenue surge guided: The Indian entity's revenue should increase by at least 30-35% in FY27 vs the previous year, with operating margin close to about 10%.
- Tech transfer pipeline: One commercial contract signed with a U.S. company to tech-transfer a legacy project from Switzerland to Bavla; activity started, to be completed within this financial year. A second major legacy project tech transfer from a prominent Swiss MNC has been approved and initiated. Three additional tech transfer projects are in advanced phase of discussion.
- Naroda site momentum: Big interest in the Naroda site; one project using an API launched in the U.S. market in July 2026 for a big MNC, which formally acknowledged the contribution. The site supported the launch of a macrocyclic peptide.
- Bavla site projects: Big projects are coming, mostly from the connection with Carbogen Amcis.
- Site credentials secured: Both Bavla and Naroda sites now hold certifications from all major international health authorities. Naroda had a U.S. FDA inspection (in observation) within the last year, and an MFDS Korea inspection was successfully completed. Two CEPs were granted from EDQM in Europe.
- Active life cycle management: Numerous transfer activities have been initiated to produce commercial products in India for higher group margins, an ongoing effort.
Commercial & Pipeline Progress
- Late-phase portfolio: More than13 late-phase projects are now in the portfolio, including PPQ campaigns. ADC-related molecules with higher priority status at the FDA have been secured.
- Phase III approval just missed Q1: One molecule from a big pharma received approval and moved to commercial stage four days after quarter-end, so it was not captured in Q1. Management calls it too premature to give a revenue number and will wait for the customer's12–24 month forecasts; the molecule received accelerated approval and looks promising.
- Three late-phase additions last quarter: Molecules were promoted from Phase I/II into Phase III.
- New commercial product: A new commercial product from big pharma was approved by the U.S. FDA, adding another commercial product to the portfolio.
- CDMO RFP activity: A steep increase in requests for proposal is underway, with several in final negotiation phase.
- SPRINT initiative: Early-phase development work at Carbogen Amcis has acquired nice and promising projects, though fruition is expected to go into the next financial year.
- Drug product traction: The drug product business is more recognized in the market, with more RFPs obtained. Management is confident of getting more business with big pharmas following positive audit outcomes at the French drug product site.
- Softgel drug product: Significant business growth over the last year; management is enthusiastic about future opportunities to build long-term CRO/CDMO partnerships.
- Bioconjugation / Celonic: The company is looking to close its first deal with Celonic as a biologics partner in the bioconjugation offering.
- Services business: The company is exploring externalizing analytics services and adding inside sales/prospecting roles to find needs.
Harshil Dalal: "I think we would have to wait for the customer's feedback on what do the forecast for the next12 months,24 months going into the future. Because initially, everybody thinks it's a blockbuster drug, but we'll just have to see."
Commercial Leadership & Go-To-Market
- New Global Chief Commercial Officer: Angela Ameriks was hired, bringing decades of CDMO experience from Hovione and Lonza; she started her sales career at the company21 years ago. From June, she is the single point of contact for Carbogen Amcis and Dishman Carbogen Amcis commercial teams, leading sales, marketing, and marketing intelligence.
- Sales team build-out: New sales leadership has been hired for India. New sales leaders were added in the past quarter across business areas. The company is actively recruiting for key roles in Europe (U.K., Central Europe). A new U.S. West Coast hire with two decades of experience starts September1st.
- Commercial focus: The stated priority is to increase prospecting efforts and work closely with existing opportunities to ensure they close. The team is about six weeks away from CPHI.
Angela Ameriks: "First and foremost, it's undeniable that we strive for more business. We need to increase our prospecting efforts and work closely with the opportunities that we have to ensure that they close."
Balance Sheet & Promoter Fundraise
- Promoter fundraise: Board and shareholder approvals have been obtained for raising up to CHF 20 crore in foreign currency at the promoter entity level, to be infused as ECB into the Indian entity. Offers from bankers are in hand; approvals were taken only after confirmation. The fundraise is expected to conclude in the next 60–90 days.
- Use of funds: The primary purpose is to prepay high-cost India debt and finance future CapEx or working capital. As soon as ECB funds are in place, the company should be able to either repay or prepay many short-term facilities, subject to lock-in periods and prepayment penalties.
- Net debt (without promoter infusion): Expected at CHF14–15 crore, reducing by ~CHF0.8–0.9 crore.
- Interest expense (without promoter infusion): INR35–40 crore per quarter, roughly INR130–140 crore for the full year.
- Overseas cash constraint: Cash on the balance sheet at overseas subsidiaries cannot be used to repay Indian parent debt due to regulatory constraints (subsidiary cannot lend to parent); it will be used at the Swiss entity level.
- Promoter share pledge: No plan to pledge shares to raise funds; if a requirement arises at the promoter entity level, it could be for a brief period or a smaller amount, but nothing concrete has been decided.
- Goodwill: Will remain on the balance sheet; tested for impairment at the end of every financial year via external valuation reports. No amortization on consolidation goodwill. [22–23]
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| FY27 group revenue growth | Single-digit growth | FY27[20–21] |
| FY27 group EBITDA margin | Similar to FY26, maybe a little bit higher | FY27 |
| Indian entity FY27 revenue growth | At least30–35% vs previous year | FY27 |
| Indian entity FY27 operating margin | Close to about10% | FY27 |
| Promoter fundraise closure | Raise funds in foreign currency, infuse as ECB | Next 60–90 days |
| FY28–29 group revenue growth | More than10% YoY | FY28–29 |
| FY28–29 group EBITDA margin | Closer to25–26% (pre-EDQM-issue levels) | FY28–29 |
| French entity and India operations growth | At least double-digit growth | FY28–29 |
| First tech transfer (Switzerland to Bavla) | Activity started, to be completed | Within FY27 |
| Japanese co-investment | Operational | Course of next calendar year |
Key Metrics
| Metric | Q1 FY27 |
|---|---|
| Revenue from operations | ₹677.6 cr, 4% YoY de-growth from ₹708 cr in Q1 FY26 |
| EBITDA | ₹60 cr, compared to ₹140.6 cr in Q1 FY26 |
| Loss before tax | ₹51.2 cr |
| Tax expense | ₹6.6 cr |
| Finance cost | ~₹37 cr, reduced vs previous quarter |
| Foreign exchange impact | ₹11.73 cr loss, mainly from USD/CHF fluctuation |
| CDMO segment revenue | ₹534.3 cr, compared to ₹611.2 cr in Q1 FY26 |
| CDMO segment EBITDA margin | 6.3%, compared to 17.9% in Q1 FY26 |
| Marketable Molecules segment revenue | ₹143.2 cr, significant growth from ₹96.8 cr in Q1 FY26 |
| Marketable Molecules segment margin | ₹1.86 cr, normalized from 32% margin in Q1 FY26 on high analogue sales |
| ADC revenue | ~₹150 cr, including linker, payload, and hyper molecule |
| CapEx | CHF 0.49 cr |
| Net debt (excluding lease liabilities) | CHF 15.36 cr as of 30 June 2026 |
| FY27 revenue growth guidance | Single-digit growth |
| FY27 EBITDA margin guidance | Similar to last year, maybe a little higher |
| FY28-29 revenue growth expectation | More than 10% YoY |
| FY28-29 EBITDA margin expectation | Closer to 25-26% |
| Indian entity FY27 revenue growth guidance | At least 30-35% YoY |
| Indian entity FY27 operating margin guidance | Close to about 10% |
| Phase III molecules commercialized in Q1 | Zero |
| Late-phase molecules promoted to Phase III | Three, from Phase I/II |
| Programs under development | 700-800 across all phases |
| Promoter fundraise approval | Up to CHF 20 cr, in multiple tranches, at 4% all-inclusive interest, 10-year tenor |
| Consolidated goodwill | In excess of ₹4,000 cr as of 31 March 2026 |